Last reviewed 2026-04-20 · How we verify

Egaten (TRICLABENDAZOLE)

Egaten works by binding to and inhibiting the enzyme responsible for the parasite's survival.

Egaten (Triclabendazole) is a small molecule anthelmintic drug developed by Novartis, targeting transthyretin to treat infections caused by Fasciola. It was FDA-approved in 2019 and remains a patented product with no generic manufacturers. Egaten works by binding to and inhibiting the enzyme responsible for the parasite's survival, ultimately leading to its death. As a result, it is used to treat fascioliasis, a disease caused by the liver fluke parasite. Key safety considerations include the potential for gastrointestinal side effects.

At a glance

Mechanism of action

Triclabendazole is an anthelmintic against Fasciola species [see Microbiology (12.4)].

Approved indications

• Infection by Fasciola

Common side effects

• abdominal pain
• hyperhidrosis
• vertigo
• nausea
• urticaria
• vomiting
• headache
• dyspnea
• pruritus
• asthenia
• musculoskeletal chest pain
• cough

Key clinical trials

• Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older). (PHASE4)
• One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis (PHASE2)
• Compassionate Use of Triclabendazole for the Treatment of Parasites (Prior to FDA Approval; Expanded Access Program)
• Impact IPT With Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine in Schoolchildren (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Egaten CI brief — competitive landscape report
• Egaten updates RSS · CI watch RSS
• Novartis portfolio CI